{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:55:30Z","timestamp":1793242530703,"version":"4.5.0"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41585-024-00948-x","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T11:03:06Z","timestamp":1729249386000},"page":"223-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6119-0889","authenticated-orcid":false,"given":"Edward Christopher","family":"Dee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenrick","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloryanne","family":"Aidoo-Micah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy B.","family":"Amen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Randy","family":"Vince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak","family":"Muralidhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Mutsvangwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth","family":"Funston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke T. A.","family":"Mounce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Pintus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosj","family":"Yamoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon A.","family":"Mahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Shamash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"948_CR1","doi-asserted-by":"publisher","first-page":"a030387","DOI":"10.1101\/cshperspect.a030387","volume":"8","author":"TR Rebbeck","year":"2018","unstructured":"Rebbeck, T. R. Prostate cancer disparities by race and ethnicity: from nucleotide to neighborhood. Cold Spring Harb. Perspect. Med. 8, a030387 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"948_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jama.2021.13304","volume":"326","author":"A Flanagin","year":"2021","unstructured":"Flanagin, A., Frey, T. & Christiansen, S. L. AMA manual of style committee. updated guidance on the reporting of race and ethnicity in medical and science journals. JAMA 326, 621\u2013627 (2021).","journal-title":"JAMA"},{"key":"948_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.eururo.2022.03.007","volume":"82","author":"YA Nyame","year":"2022","unstructured":"Nyame, Y. A. et al. Deconstructing, addressing, and eliminating racial and ethnic inequities in prostate cancer care. Eur. Urol. 82, 341\u2013351 (2022).","journal-title":"Eur. Urol."},{"key":"948_CR4","unstructured":"Daniszewski, J. The decision to capitalize Black. Associated Press https:\/\/blog.ap.org\/announcements\/the-decision-to-capitalize-black (2024)."},{"key":"948_CR5","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1002\/cncr.34346","volume":"128","author":"EC Dee","year":"2022","unstructured":"Dee, E. C., Pierce, L. J., Winkfield, K. M. & Lam, M. B. In pursuit of equity in cancer care: moving beyond the affordable care act. Cancer 128, 3278\u20133283 (2022).","journal-title":"Cancer"},{"key":"948_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41416-020-01038-6","volume":"124","author":"VA Zavala","year":"2021","unstructured":"Zavala, V. A. et al. Cancer health disparities in racial\/ethnic minorities in the United States. Br. J. Cancer 124, 315\u2013332 (2021).","journal-title":"Br. J. Cancer"},{"key":"948_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3322\/caac.21555","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis, C. E., Miller, K. D., Goding Sauer, A., Jemal, A. & Siegel, R. L. Cancer statistics for African Americans, 2019. CA Cancer J. Clin. 69, 211\u2013233 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"948_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/pros.20052","volume":"62","author":"SJ Freedland","year":"2005","unstructured":"Freedland, S. J. & Isaacs, W. B. Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate 62, 243\u2013252 (2005).","journal-title":"Prostate"},{"key":"948_CR9","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1200\/OP.23.00040","volume":"19","author":"HY Hougen","year":"2023","unstructured":"Hougen, H. Y. et al. Disparities in diagnosis, treatment access, and time to treatment among Hispanic men with metastatic prostate cancer. JCO Oncol. Pract. 19, 645\u2013653 (2023).","journal-title":"JCO Oncol. Pract."},{"key":"948_CR10","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/pros.24041","volume":"80","author":"EC Dee","year":"2020","unstructured":"Dee, E. C. et al. Prostate cancer-specific mortality burden by risk group among men with localized disease: implications for research and clinical trial priorities. Prostate 80, 1128\u20131133 (2020).","journal-title":"Prostate"},{"key":"948_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10552-019-01159-1","volume":"30","author":"AG Cuevas","year":"2019","unstructured":"Cuevas, A. G. et al. Placing prostate cancer disparities within a psychosocial context: challenges and opportunities for future research. Cancer Causes Control. 30, 443\u2013456 (2019).","journal-title":"Cancer Causes Control."},{"key":"948_CR12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s10552-012-9988-8","volume":"23","author":"JM Major","year":"2012","unstructured":"Major, J. M. et al. Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study. Cancer Causes Control. 23, 1185\u20131191 (2012).","journal-title":"Cancer Causes Control."},{"key":"948_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11113-016-9416-y","volume":"36","author":"H Sohn","year":"2017","unstructured":"Sohn, H. Racial and ethnic disparities in health insurance coverage: dynamics of gaining and losing coverage over the life-course. Popul. Res. Policy Rev. 36, 181\u2013201 (2017).","journal-title":"Popul. Res. Policy Rev."},{"key":"948_CR14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1158\/1055-9965.EPI-19-1344","volume":"29","author":"S Iyengar","year":"2020","unstructured":"Iyengar, S., Hall, I. J. & Sabatino, S. A. Racial\/ethnic disparities in prostate cancer incidence, distant stage diagnosis, and mortality by U.S. census region and age-group, 2012\u20132015. Cancer Epidemiol. Biomark. Prev. 29, 1357\u20131364 (2020).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"948_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41391-022-00526-5","volume":"26","author":"N Swami","year":"2023","unstructured":"Swami, N. et al. Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men. Prostate Cancer Prostatic Dis. 26, 309\u2013316 (2023).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"948_CR16","first-page":"455","volume":"8","author":"AL Jones","year":"2014","unstructured":"Jones, A. L. & Chinegwundoh, F. Update on prostate cancer in black men within the UK. Ecancermedicalscience 8, 455 (2014).","journal-title":"Ecancermedicalscience"},{"key":"948_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0405-5","volume":"13","author":"T Lloyd","year":"2015","unstructured":"Lloyd, T. et al. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008\u20132010. BMC Med. 13, 171 (2015).","journal-title":"BMC Med."},{"key":"948_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062079","volume":"13","author":"A Fry","year":"2023","unstructured":"Fry, A., White, B., Nagarwalla, D., Shelton, J. & Jack, R. H. Relationship between ethnicity and stage at diagnosis in England: a national analysis of six cancer sites. BMJ Open. 13, e062079 (2023).","journal-title":"BMJ Open."},{"key":"948_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10920277.2003.10596082","volume":"7","author":"HJ Bolnick","year":"2003","unstructured":"Bolnick, H. J. Designing a world-class health care system. North. Am. Actuarial J. 7, 1\u201323 (2003).","journal-title":"North. Am. Actuarial J."},{"key":"948_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.eururo.2007.02.047","volume":"53","author":"Y Ben-Shlomo","year":"2008","unstructured":"Ben-Shlomo, Y. et al. The risk of prostate cancer amongst black men in the United Kingdom: the PROCESS cohort study. Eur. Urol. 53, 99\u2013105 (2008).","journal-title":"Eur. Urol."},{"key":"948_CR21","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/sj.bjc.6604670","volume":"99","author":"C Metcalfe","year":"2008","unstructured":"Metcalfe, C. et al. Pathways to diagnosis for Black men and White men found to have prostate cancer: the PROCESS cohort study. Br. J. Cancer 99, 1040\u20131045 (2008).","journal-title":"Br. J. Cancer"},{"key":"948_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp, M. B., Soerjomataram, I., Efstathiou, J. A., Bray, F. & Jemal, A. Recent global patterns in prostate cancer incidence and mortality rates. Eur. Urol. 77, 38\u201352 (2020).","journal-title":"Eur. Urol."},{"key":"948_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrurol.2015.298","volume":"13","author":"KF McGinley","year":"2016","unstructured":"McGinley, K. F., Tay, K. J. & Moul, J. W. Prostate cancer in men of African origin. Nat. Rev. Urol. 13, 99\u2013107 (2016).","journal-title":"Nat. Rev. Urol."},{"key":"948_CR24","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s42003-021-02140-y","volume":"4","author":"W Rayford","year":"2021","unstructured":"Rayford, W. et al. Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Commun. Biol. 4, 670 (2021).","journal-title":"Commun. Biol."},{"key":"948_CR25","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1001\/jama.1994.03510430091042","volume":"271","author":"E Friedman","year":"1994","unstructured":"Friedman, E. Money isn\u2019t everything: nonfinancial barriers to access. JAMA 271, 1535\u20131538 (1994).","journal-title":"JAMA"},{"key":"948_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2190\/HS.38.4.f","volume":"38","author":"J Schnittker","year":"2008","unstructured":"Schnittker, J. & Bhatt, M. The role of income and race\/ethnicity in experiences with medical care in the United States and United Kingdom. Int. J. Health Serv. 38, 671\u2013695 (2008).","journal-title":"Int. J. Health Serv."},{"key":"948_CR27","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMms2029562","volume":"384","author":"LN Borrell","year":"2021","unstructured":"Borrell L. N., et al. Race and genetic ancestry in medicine \u2014 a time for reckoning with racism. N. Engl. J. Med. 384, 474\u2013480 (2021).","journal-title":"N. Engl. J."},{"key":"948_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41391-022-00613-7","volume":"26","author":"M Barlow","year":"2023","unstructured":"Barlow, M. et al. Ethnic differences in prostate-specific antigen levels in men without prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 26, 249\u2013256 (2023).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"948_CR29","first-page":"1","volume":"379","author":"DA Lacher","year":"2006","unstructured":"Lacher, D. A., Thompson, T. D., Hughes, J. P. & Saraiya, M. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001\u201304. Adv. Data 379, 1\u201312 (2006).","journal-title":"Adv. Data"},{"key":"948_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0090-4295(96)00091-X","volume":"48","author":"EP DeAntoni","year":"1996","unstructured":"DeAntoni, E. P. et al. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology 48, 234\u2013239 (1996).","journal-title":"Urology"},{"key":"948_CR31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.urology.2013.10.051","volume":"83","author":"R Espaldon","year":"2014","unstructured":"Espaldon, R. et al. Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold. Urology 83, 599\u2013605 (2014).","journal-title":"Urology"},{"key":"948_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.cca.2015.06.009","volume":"448","author":"DA Lacher","year":"2015","unstructured":"Lacher, D. A. & Hughes, J. P. Total, free, and complexed prostate-specific antigen levels among US men, 2007\u20132010. Clin. Chim. Acta 448, 220\u2013227 (2015).","journal-title":"Clin. Chim. Acta"},{"key":"948_CR33","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0090-4295(98)00448-8","volume":"52","author":"MC Weinrich","year":"1998","unstructured":"Weinrich, M. C. et al. Reference ranges for serum prostate-specific antigen in black and white men without cancer. Urology 52, 967\u2013973 (1998).","journal-title":"Urology"},{"key":"948_CR34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.juro.2011.09.061","volume":"187","author":"T Rhodes","year":"2012","unstructured":"Rhodes, T. et al. Benign prostate specific antigen distribution and associations with urological outcomes in community dwelling black and white men. J. Urol. 187, 87\u201391 (2012).","journal-title":"J. Urol."},{"key":"948_CR35","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/j.1464-410X.2011.10224.x","volume":"108","author":"ED Crawford","year":"2011","unstructured":"Crawford, E. D. et al. Prostate-specific antigen 1.5\u20134.0 ng\/mL: a diagnostic challenge and danger zone. BJU Int. 108, 1743\u20131749 (2011).","journal-title":"BJU Int."},{"key":"948_CR36","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1158\/1055-9965.EPI-05-0206","volume":"14","author":"M Saraiya","year":"2005","unstructured":"Saraiya, M. et al. Total and percent free prostate-specific antigen levels among U.S. men, 2001\u20132002. Cancer Epidemiol. Biomark. Prev. 14, 2178\u20132182 (2005).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"948_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.urology.2013.08.025","volume":"83","author":"AV Sarma","year":"2014","unstructured":"Sarma, A. V. et al. Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County study and the Flint men\u2019s health study. Urology 83, 88\u201393 (2014).","journal-title":"Urology"},{"key":"948_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.juro.2011.09.060","volume":"187","author":"T Rhodes","year":"2012","unstructured":"Rhodes, T. et al. Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men. J. Urol. 187, 92\u201396 (2012).","journal-title":"J. Urol."},{"key":"948_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03283-5","volume":"22","author":"L Down","year":"2024","unstructured":"Down, L. et al. Association between patient ethnicity and prostate cancer diagnosis following a prostate-specific antigen test: a cohort study of 730,000 men in primary care in the UK. BMC Med. 22, 82 (2024).","journal-title":"BMC Med."},{"key":"948_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.prnil.2016.07.001","volume":"4","author":"S Hassanipour-Azgomi","year":"2016","unstructured":"Hassanipour-Azgomi, S. et al. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate Int. 4, 118\u2013124 (2016).","journal-title":"Prostate Int."},{"key":"948_CR41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.eururo.2022.11.019","volume":"83","author":"MN Brook","year":"2023","unstructured":"Brook, M. N. et al. Family history of prostate cancer and survival outcomes in the UK genetic prostate cancer study. Eur. Urol. 83, 257\u2013266 (2023).","journal-title":"Eur. Urol."},{"key":"948_CR42","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1634\/theoncologist.2019-0804","volume":"25","author":"LG Qu","year":"2020","unstructured":"Qu, L. G., Brand, N. R., Chao, A. & Ilbawi, A. M. Interventions addressing barriers to delayed cancer diagnosis in low\u2010 and middle\u2010income countries: a systematic review. Oncologist 25, e1382\u2013e1395 (2020).","journal-title":"Oncologist"},{"key":"948_CR43","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schr\u00f6der","year":"2014","unstructured":"Schr\u00f6der, F. H. et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384, 2027\u20132035 (2014).","journal-title":"Lancet"},{"key":"948_CR44","doi-asserted-by":"publisher","first-page":"762","DOI":"10.7326\/0003-4819-155-11-201112060-00375","volume":"155","author":"R Chou","year":"2011","unstructured":"Chou, R. et al. Screening for prostate cancer: a review of the evidence for the U.S. preventive services task force. Ann. Intern. Med. 155, 762\u2013771 (2011).","journal-title":"Ann. Intern. Med."},{"key":"948_CR45","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.juro.2015.06.075","volume":"194","author":"DA Barocas","year":"2015","unstructured":"Barocas, D. A. et al. Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States. J. Urol. 194, 1587\u20131593 (2015).","journal-title":"J. Urol."},{"key":"948_CR46","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.11869","volume":"5","author":"L Burgess","year":"2022","unstructured":"Burgess, L. et al. Association of the USPSTF grade D recommendation against prostate-specific antigen screening with prostate cancer-specific mortality. JAMA Netw. Open. 5, e2211869 (2022).","journal-title":"JAMA Netw. Open."},{"key":"948_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/jamaoncol.2021.5143","volume":"8","author":"MS Leapman","year":"2022","unstructured":"Leapman, M. S. et al. Changes in prostate-specific antigen testing relative to the revised US preventive services task force recommendation on prostate cancer screening. JAMA Oncol. 8, 41\u201347 (2022).","journal-title":"JAMA Oncol."},{"key":"948_CR48","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1002\/cncr.33179","volume":"126","author":"IE Kim","year":"2020","unstructured":"Kim, I. E. et al. Abrogation of survival disparity between Black and White individuals after the USPSTF\u2019s 2012 prostate-specific antigen-based prostate cancer screening recommendation. Cancer 126, 5114\u20135123 (2020).","journal-title":"Cancer"},{"key":"948_CR49","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41585-023-00849-5","volume":"21","author":"JR Johnson","year":"2024","unstructured":"Johnson, J. R. et al. The complex interplay of modifiable risk factors affecting prostate cancer disparities in African American men. Nat. Rev. Urol. 21, 422\u2013432 (2024).","journal-title":"Nat. Rev. Urol."},{"key":"948_CR50","doi-asserted-by":"publisher","first-page":"EVIDoa2300289","DOI":"10.1056\/EVIDoa2300289","volume":"3","author":"IP Garraway","year":"2024","unstructured":"Garraway, I. P. et al. Prostate cancer foundation screening guidelines for black men in the United States. NEJM Evid. 3, EVIDoa2300289 (2024).","journal-title":"NEJM Evid."},{"key":"948_CR51","unstructured":"Office for Health Improvement & Disparities. PSA testing and prostate cancer: advice for men without symptoms of prostate disease aged 50 and over. GOV.UK https:\/\/www.gov.uk\/government\/publications\/prostate-specific-antigen-testing-description-in-brief\/psa-testing-and-prostate-cancer-advice-for-men-without-symptoms-of-prostate-disease-aged-50-and-over (2022)."},{"key":"948_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071076","volume":"377","author":"SH Bradley","year":"2022","unstructured":"Bradley, S. H., Funston, G., Jones, D. & Watson, J. Diagnosing prostate cancer in asymptomatic patients. BMJ 377, e071076 (2022).","journal-title":"BMJ"},{"key":"948_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1464-4096.2004.04832.x","volume":"94","author":"J Melia","year":"2004","unstructured":"Melia, J., Moss, S. & Johns, L. Contributors in the participating laboratories. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int. 94, 51\u201356 (2004).","journal-title":"BJU Int."},{"key":"948_CR54","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1464-410X.2011.10163.x","volume":"108","author":"N Williams","year":"2011","unstructured":"Williams, N. et al. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. BJU Int. 108, 1402\u20131408 (2011).","journal-title":"BJU Int."},{"key":"948_CR55","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.healthpol.2012.08.014","volume":"108","author":"R Burns","year":"2012","unstructured":"Burns, R., Walsh, B., O\u2019Neill, S. & O\u2019Neill, C. An examination of variations in the uptake of prostate cancer screening within and between the countries of the EU-27. Health Policy 108, 268\u2013276 (2012).","journal-title":"Health Policy"},{"key":"948_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011356","volume":"6","author":"P Nderitu","year":"2016","unstructured":"Nderitu, P. et al. Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested? BMJ Open. 6, e011356 (2016).","journal-title":"BMJ Open."},{"key":"948_CR57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1258\/jms.2010.009112","volume":"17","author":"K Robb","year":"2010","unstructured":"Robb, K. et al. Ethnic disparities in knowledge of cancer screening programmes in the UK. J. Med. Screen. 17, 125\u2013131 (2010).","journal-title":"J. Med. Screen."},{"key":"948_CR58","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.3399\/bjgp15X683965","volume":"65","author":"T Martins","year":"2015","unstructured":"Martins, T., Ukoumunne, O. C., Banks, J., Raine, R. & Hamilton, W. Ethnic differences in patients\u2019 preferences for prostate cancer investigation: a vignette-based survey in primary care. Br. J. Gen. Pract. 65, e161\u2013e170 (2015).","journal-title":"Br. J. Gen. Pract."},{"key":"948_CR59","unstructured":"Volunteer Voices. \u2018I have prostate cancer. By signing up to our future health I\u2019m hoping I can help my sons\u2019 chances of beating the disease\u2019. Our Future Health https:\/\/ourfuturehealth.org.uk\/news\/i-have-prostate-cancer-by-signing-up-to-our-future-health-im-hoping-i-can-help-my-sons-chances-of-beating-the-disease\/ (2023)."},{"key":"948_CR60","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1001\/jama.2018.14438","volume":"320","author":"PB Fontanarosa","year":"2018","unstructured":"Fontanarosa, P. B. & Bauchner, H. Race, ancestry, and medical research. JAMA 320, 1539\u20131540 (2018).","journal-title":"JAMA"},{"key":"948_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello, R. J. et al. Prostate cancer. Nat. Rev. Dis. Primers 7, 1\u201327 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"948_CR62","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.eururo.2016.05.043","volume":"70","author":"MCS Wong","year":"2016","unstructured":"Wong, M. C. S. et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 Countries. Eur. Urol. 70, 862\u2013874 (2016).","journal-title":"Eur. Urol."},{"key":"948_CR63","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/pcan.2012.53","volume":"16","author":"SA Fedewa","year":"2013","unstructured":"Fedewa, S. A. & Jemal, A. Prostate cancer disease severity and country of origin among black men in the United States. Prostate Cancer Prostatic Dis. 16, 176\u2013180 (2013).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"948_CR64","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/j.1464-410X.2008.08265.x","volume":"103","author":"KCM Coard","year":"2009","unstructured":"Coard, K. C. M. & Skeete, D. H. A. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica. BJU Int. 103, 1482\u20131486 (2009).","journal-title":"BJU Int."},{"key":"948_CR65","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.urolonc.2011.01.018","volume":"31","author":"J Yarney","year":"2013","unstructured":"Yarney, J., Vanderpuye, V. & Mensah, J. Clinicopathologic features and determinants of Gleason score of prostate cancer in Ghanaian men. Urol. Oncol. 31, 325\u2013330 (2013).","journal-title":"Urol. Oncol."},{"key":"948_CR66","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4103\/1119-3077.86785","volume":"14","author":"CC Obiorah","year":"2011","unstructured":"Obiorah, C. C. & Nwosu, S. O. A histopathological study of carcinoma of the prostate in Port Harcourt, Nigeria. Niger. J. Clin. Pract. 14, 363\u2013367 (2011).","journal-title":"Niger. J. Clin. Pract."},{"key":"948_CR67","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/bjc.2011.273","volume":"105","author":"P Kheirandish","year":"2011","unstructured":"Kheirandish, P. & Chinegwundoh, F. Ethnic differences in prostate cancer. Br. J. Cancer 105, 481\u2013485 (2011).","journal-title":"Br. J. Cancer"},{"key":"948_CR68","doi-asserted-by":"publisher","first-page":"14068","DOI":"10.1073\/pnas.0605832103","volume":"103","author":"ML Freedman","year":"2006","unstructured":"Freedman, M. L. et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc. Natl Acad. Sci. USA 103, 14068\u201314073 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"948_CR69","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/ng2015","volume":"39","author":"CA Haiman","year":"2007","unstructured":"Haiman, C. A. et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 39, 638\u2013644 (2007).","journal-title":"Nat. Genet."},{"key":"948_CR70","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/ng1808","volume":"38","author":"LT Amundadottir","year":"2006","unstructured":"Amundadottir, L. T. et al. A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38, 652\u2013658 (2006).","journal-title":"Nat. Genet."},{"key":"948_CR71","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1158\/0008-5472.CAN-17-1550","volume":"78","author":"J Lachance","year":"2018","unstructured":"Lachance, J. et al. Genetic hitchhiking and population bottlenecks contribute to prostate cancer disparities in men of African descent. Cancer Res. 78, 2432\u20132443 (2018).","journal-title":"Cancer Res."},{"key":"948_CR72","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/pros.22612","volume":"73","author":"E Taioli","year":"2013","unstructured":"Taioli, E. et al. Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent. Prostate 73, 668\u2013676 (2013).","journal-title":"Prostate"},{"key":"948_CR73","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1158\/1055-9965.EPI-13-0568","volume":"23","author":"JB Hjelmborg","year":"2014","unstructured":"Hjelmborg, J. B. et al. The heritability of prostate cancer in the Nordic Twin Study of Cancer. Cancer Epidemiol. Biomark. Prev. 23, 2303\u20132310 (2014).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"948_CR74","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/s41588-023-01534-4","volume":"55","author":"A Wang","year":"2023","unstructured":"Wang, A. et al. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat. Genet. 55, 2065\u20132074 (2023).","journal-title":"Nat. Genet."},{"key":"948_CR75","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","volume":"53","author":"DV Conti","year":"2021","unstructured":"Conti, D. V. et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat. Genet. 53, 65\u201375 (2021).","journal-title":"Nat. Genet."},{"key":"948_CR76","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","volume":"50","author":"FR Schumacher","year":"2018","unstructured":"Schumacher, F. R. et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat. Genet. 50, 928\u2013936 (2018).","journal-title":"Nat. Genet."},{"key":"948_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04109-8","volume":"9","author":"T Dadaev","year":"2018","unstructured":"Dadaev, T. et al. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat. Commun. 9, 2256 (2018).","journal-title":"Nat. Commun."},{"key":"948_CR78","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMc2000069","volume":"383","author":"BA Mahal","year":"2020","unstructured":"Mahal, B. A. et al. Racial differences in genomic profiling of prostate cancer. N. Engl. J. Med. 383, 1083\u20131085 (2020).","journal-title":"N. Engl. J. Med."},{"key":"948_CR79","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.eururo.2019.01.010","volume":"75","author":"BA Mahal","year":"2019","unstructured":"Mahal, B. A. et al. Prostate cancer genomic-risk differences between African-American and white men across Gleason scores. Eur. Urol. 75, 1038\u20131040 (2019).","journal-title":"Eur. Urol."},{"key":"948_CR80","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.18.01279","volume":"37","author":"S Halabi","year":"2019","unstructured":"Halabi, S. et al. Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel. J. Clin. Oncol. 37, 403\u2013410 (2019).","journal-title":"J. Clin. Oncol."},{"key":"948_CR81","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44027","volume":"5","author":"K Yamoah","year":"2022","unstructured":"Yamoah, K. et al. Racial and ethnic disparities in prostate cancer outcomes in the veterans affairs health care system. JAMA Netw. Open. 5, e2144027 (2022).","journal-title":"JAMA Netw. Open."},{"key":"948_CR82","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO.2014.58.1751","volume":"33","author":"DE Spratt","year":"2015","unstructured":"Spratt, D. E. & Osborne, J. R. Disparities in castration-resistant prostate cancer trials. J. Clin. Oncol. 33, 1101\u20131103 (2015).","journal-title":"J. Clin. Oncol."},{"key":"948_CR83","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/1055-9965.EPI-19-1616","volume":"29","author":"EM Rencsok","year":"2020","unstructured":"Rencsok, E. M. et al. Diversity of enrollment in prostate cancer clinical trials: current status and future directions. Cancer Epidemiol. Biomark. Prev. 29, 1374\u20131380 (2020).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"948_CR84","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3390\/genes11121471","volume":"11","author":"DD Lewis","year":"2020","unstructured":"Lewis, D. D. & Cropp, C. D. The impact of African ancestry on prostate cancer disparities in the era of precision medicine. Genes 11, 1471 (2020).","journal-title":"Genes"},{"key":"948_CR85","first-page":"431","volume":"14","author":"G Maskarinec","year":"2004","unstructured":"Maskarinec, G. & Noh, J. J. The effect of migration on cancer incidence among Japanese in Hawaii. Ethn. Dis. 14, 431\u2013439 (2004).","journal-title":"Ethn. Dis."},{"key":"948_CR86","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/1055-9965.EPI-05-0614","volume":"15","author":"C Rodriguez","year":"2006","unstructured":"Rodriguez, C. et al. Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol. Biomark. Prev. 15, 211\u2013216 (2006).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"948_CR87","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/1940-6207.CAPR-16-0070","volume":"9","author":"KM Wilson","year":"2016","unstructured":"Wilson, K. M. et al. Meat, fish, poultry, and egg intake at diagnosis and risk of prostate cancer progression. Cancer Prev. Res. 9, 933\u2013941 (2016).","journal-title":"Cancer Prev. Res."},{"key":"948_CR88","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/jamaoncol.2015.0513","volume":"1","author":"WE Barrington","year":"2015","unstructured":"Barrington, W. E. et al. Difference in association of obesity with prostate cancer risk between US African American and non-Hispanic white men in the selenium and vitamin E cancer prevention trial (SELECT). JAMA Oncol. 1, 342\u2013349 (2015).","journal-title":"JAMA Oncol."},{"key":"948_CR89","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1200\/JCO.2004.03.132","volume":"22","author":"CL Amling","year":"2004","unstructured":"Amling, C. L. et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J. Clin. Oncol. 22, 439\u2013445 (2004).","journal-title":"J. Clin. Oncol."},{"key":"948_CR90","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/oby.23640","volume":"31","author":"H Lofton","year":"2023","unstructured":"Lofton, H., Ard, J. D., Hunt, R. R. & Knight, M. G. Obesity among African American people in the United States: a review. Obesity 31, 306\u2013315 (2023).","journal-title":"Obesity"},{"key":"948_CR91","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(17)30569-X","volume":"389","author":"ZD Bailey","year":"2017","unstructured":"Bailey, Z. D. et al. Structural racism and health inequities in the USA: evidence and interventions. Lancet 389, 1453\u20131463 (2017).","journal-title":"Lancet"},{"key":"948_CR92","doi-asserted-by":"publisher","DOI":"10.1177\/15579883231205845","volume":"17","author":"H Zare","year":"2023","unstructured":"Zare, H., Aazami, A., Shalby, N., Gilmore, D. R. & Thorpe, R. J. Measuring racial differences in obesity risk factors in non-Hispanic black and white men aged 20 years or older. Am. J. Mens. Health 17, 15579883231205845 (2023).","journal-title":"Am. J. Mens. Health"},{"key":"948_CR93","unstructured":"Office for Health Improvement & Disparities. Obesity Profile: short statistical commentary May 2023. GOV.UK https:\/\/www.gov.uk\/government\/statistics\/obesity-profile-update-may-2023\/obesity-profile-short-statistical-commentary-may-2023 (2023)."},{"key":"948_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09386-9","volume":"7","author":"I G\u00f3mez-Acebo","year":"2017","unstructured":"G\u00f3mez-Acebo, I. et al. Risk model for prostate cancer using environmental and genetic factors in the Spanish Multi-Case-Control (MCC) study. Sci. Rep. 7, 8994 (2017).","journal-title":"Sci. Rep."},{"key":"948_CR95","doi-asserted-by":"publisher","DOI":"10.1172\/JCI155031","volume":"132","author":"WG Nelson","year":"2022","unstructured":"Nelson, W. G. et al. Health inequity drives disease biology to create disparities in prostate cancer outcomes. J. Clin. Invest. 132, e155031 (2022).","journal-title":"J. Clin. Invest."},{"key":"948_CR96","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/pros.24133","volume":"81","author":"MC Bosland","year":"2021","unstructured":"Bosland, M. C. et al. Prevalence of prostate cancer at autopsy in Nigeria \u2014 a preliminary report. Prostate 81, 553\u2013559 (2021).","journal-title":"Prostate"},{"key":"948_CR97","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1002\/ijc.29408","volume":"137","author":"JL Jahn","year":"2015","unstructured":"Jahn, J. L., Giovannucci, E. L. & Stampfer, M. J. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era. Int. J. Cancer 137, 2795\u20132802 (2015).","journal-title":"Int. J. Cancer"},{"key":"948_CR98","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrg2881","volume":"11","author":"SE Johnstone","year":"2010","unstructured":"Johnstone, S. E. & Baylin, S. B. Stress and the epigenetic landscape: a link to the pathobiology of human diseases? Nat. Rev. Genet. 11, 806\u2013812 (2010).","journal-title":"Nat. Rev. Genet."},{"key":"948_CR99","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40471-017-0096-x","volume":"4","author":"AD Vick","year":"2017","unstructured":"Vick, A. D. & Burris, H. H. Epigenetics and health disparities. Curr. Epidemiol. Rep. 4, 31\u201337 (2017).","journal-title":"Curr. Epidemiol. Rep."},{"key":"948_CR100","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrc2090","volume":"7","author":"AM De Marzo","year":"2007","unstructured":"De Marzo, A. M. et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7, 256\u2013269 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"948_CR101","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/1078-0432.CCR-20-2925","volume":"27","author":"S Awasthi","year":"2021","unstructured":"Awasthi, S. et al. Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer. Clin. Cancer Res. 27, 320\u2013329 (2021).","journal-title":"Clin. Cancer Res."},{"key":"948_CR102","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1158\/1055-9965.EPI-12-1238","volume":"22","author":"IJ Powell","year":"2013","unstructured":"Powell, I. J. et al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol. Biomark. Prev. 22, 891\u2013897 (2013).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"948_CR103","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41416-020-0859-x","volume":"123","author":"EN Butler","year":"2020","unstructured":"Butler, E. N., Kelly, S. P., Coupland, V. H., Rosenberg, P. S. & Cook, M. B. Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment. Br. J. Cancer 123, 487\u2013494 (2020).","journal-title":"Br. J. Cancer"},{"key":"948_CR104","doi-asserted-by":"publisher","first-page":"e1489","DOI":"10.1200\/OP.20.00839","volume":"17","author":"EC Dee","year":"2021","unstructured":"Dee, E. C. et al. Disparities in refusal of locoregional treatment for prostate adenocarcinoma. JCO Oncol. Pract. 17, e1489\u2013e1501 (2021).","journal-title":"JCO Oncol. Pract."},{"key":"948_CR105","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41391-021-00479-1","volume":"25","author":"B Jain","year":"2022","unstructured":"Jain, B. et al. Racial disparities in treatment delay among younger men with prostate cancer. Prostate Cancer Prostatic Dis. 25, 590\u2013592 (2022).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"948_CR106","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ijrobp.2020.11.064","volume":"109","author":"EC Dee","year":"2021","unstructured":"Dee, E. C. et al. Factors influencing noncompletion of radiation therapy among men with localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 109, 1279\u20131285 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"948_CR107","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1200\/OP.22.00383","volume":"19","author":"EC Dee","year":"2023","unstructured":"Dee, E. C. et al. Shorter radiation regimens and treatment noncompletion among patients with breast and prostate cancer in the United States: an analysis of racial disparities in access and quality. JCO Oncol. Pract. 19, e197\u2013e212 (2023).","journal-title":"JCO Oncol. Pract."},{"key":"948_CR108","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1002\/pros.24228","volume":"81","author":"S Chhatre","year":"2021","unstructured":"Chhatre, S., Malkowicz, S. B. & Jayadevappa, R. Continuity of care in acute survivorship phase, and short and long-term outcomes in prostate cancer patients. Prostate 81, 1310\u20131319 (2021).","journal-title":"Prostate"},{"key":"948_CR109","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2017.74.2049","volume":"36","author":"L Ellis","year":"2018","unstructured":"Ellis, L. et al. Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics. J. Clin. Oncol. 36, 25\u201333 (2018).","journal-title":"J. Clin. Oncol."},{"key":"948_CR110","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.2852","volume":"7","author":"A Wadhwa","year":"2024","unstructured":"Wadhwa, A. et al. Neighborhood deprivation, race and ethnicity, and prostate cancer outcomes across California health care systems. JAMA Netw. Open. 7, e242852 (2024).","journal-title":"JAMA Netw. Open."},{"key":"948_CR111","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/sj.bjc.6605461","volume":"102","author":"S Evans","year":"2010","unstructured":"Evans, S. et al. Clinical presentation and initial management of Black men and White men with prostate cancer in the United Kingdom: the PROCESS cohort study. Br. J. Cancer 102, 249\u2013254 (2010).","journal-title":"Br. J. Cancer"},{"key":"948_CR112","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41391-020-00313-0","volume":"24","author":"F Kum","year":"2021","unstructured":"Kum, F. et al. Presentation, follow-up, and outcomes among African\/Afro-Caribbean men on active surveillance for prostate cancer: experiences of a high-volume UK centre. Prostate Cancer Prostatic Dis. 24, 549\u2013557 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"948_CR113","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","volume":"5","author":"RT Dess","year":"2019","unstructured":"Dess, R. T. et al. Association of black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 5, 975\u2013983 (2019).","journal-title":"JAMA Oncol."},{"key":"948_CR114","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/cncr.32666","volume":"126","author":"P Riviere","year":"2020","unstructured":"Riviere, P. et al. Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system. Cancer 126, 1683\u20131690 (2020).","journal-title":"Cancer"},{"key":"948_CR115","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1002\/cam4.4787","volume":"11","author":"N Oehrlein","year":"2022","unstructured":"Oehrlein, N. et al. Race-specific prostate cancer outcomes in a cohort of military health care beneficiaries undergoing surgery: 1990\u20132017. Cancer Med. 11, 4354\u20134365 (2022).","journal-title":"Cancer Med."},{"key":"948_CR116","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.2020.38.6_suppl.327","volume":"38","author":"AU Kishan","year":"2020","unstructured":"Kishan, A. U. et al. Association of black race with improved outcomes following definitive radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a meta-analysis of eight randomized trials. J. Clin. Oncol. 38, 327\u2013327 (2020).","journal-title":"J. Clin. Oncol."},{"key":"948_CR117","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1001\/jama.2018.11716","volume":"320","author":"BA Mahal","year":"2018","unstructured":"Mahal, B. A., Berman, R. A., Taplin, M. E. & Huang, F. W. Prostate cancer-specific mortality across Gleason scores in black vs nonblack men. JAMA 320, 2479\u20132481 (2018).","journal-title":"JAMA"},{"key":"948_CR118","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1001\/jama.2020.17020","volume":"324","author":"R Deka","year":"2020","unstructured":"Deka, R. et al. Association between African American race and clinical outcomes in men treated for low-risk prostate cancer with active surveillance. JAMA 324, 1747\u20131754 (2020).","journal-title":"JAMA"},{"key":"948_CR119","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jamaoncol.2021.8116","volume":"8","author":"MS Leapman","year":"2022","unstructured":"Leapman, M. S. et al. Mediators of racial disparity in the use of prostate magnetic resonance imaging among patients with prostate cancer. JAMA Oncol. 8, 687\u2013696 (2022).","journal-title":"JAMA Oncol."},{"key":"948_CR120","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.50416","volume":"6","author":"RA Vince","year":"2023","unstructured":"Vince, R. A. et al. Evaluation of social determinants of health and prostate cancer outcomes among black and white patients: a systematic review and meta-analysis. JAMA Netw. Open. 6, e2250416 (2023).","journal-title":"JAMA Netw. Open."},{"key":"948_CR121","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/jnci\/93.3.219","volume":"93","author":"I Thompson","year":"2001","unstructured":"Thompson, I. et al. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J. Natl Cancer Inst. 93, 219\u2013225 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"948_CR122","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.juro.2012.06.046","volume":"188","author":"CM Tangen","year":"2012","unstructured":"Tangen, C. M. et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J. Urol. 188, 1164\u20131169 (2012).","journal-title":"J. Urol."},{"key":"948_CR123","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41391-023-00710-1","volume":"26","author":"SJ Freedland","year":"2023","unstructured":"Freedland, S. J. et al. The impact of race on survival in metastatic prostate cancer: a systematic literature review. Prostate Cancer Prostatic Dis. 26, 461\u2013474 (2023).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"948_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.07.518","volume":"108","author":"V Muralidhar","year":"2020","unstructured":"Muralidhar, V. et al. Association between black race and improved survival following sipuleucel-T immunotherapy in metastatic castrate-resistant prostate cancer: implications for immune biology and integration of radiation therapy with immunotherapy. Int. J. Radiat. Oncol. Biol. Phys. 108, e901 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"948_CR125","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41391-020-0213-7","volume":"23","author":"O Sartor","year":"2020","unstructured":"Sartor, O. et al. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 23, 517\u2013526 (2020).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"948_CR126","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/JU.0000000000000524","volume":"203","author":"H Zhao","year":"2020","unstructured":"Zhao, H. et al. Racial discrepancies in overall survival among men treated with 223radium. J. Urol. 203, 331\u2013337 (2020).","journal-title":"J. Urol."},{"key":"948_CR127","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.42093","volume":"5","author":"M Marar","year":"2022","unstructured":"Marar, M. et al. Outcomes among African American and non-Hispanic white men with metastatic castration-resistant prostate cancer with first-line abiraterone. JAMA Netw. Open. 5, e2142093 (2022).","journal-title":"JAMA Netw. Open."},{"key":"948_CR128","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41391-020-00316-x","volume":"24","author":"K Ng","year":"2021","unstructured":"Ng, K., Wilson, P., Mutsvangwa, K., Hounsome, L. & Shamash, J. Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England. Prostate Cancer Prostatic Dis. 24, 718\u2013724 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"948_CR129","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1200\/JCO.2014.57.1349","volume":"33","author":"ET Warner","year":"2015","unstructured":"Warner, E. T. et al. Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J. Clin. Oncol. 33, 2254\u20132261 (2015).","journal-title":"J. Clin. Oncol."},{"key":"948_CR130","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2217\/fon-2021-0992","volume":"18","author":"D Pilon","year":"2022","unstructured":"Pilon, D. et al. Medication adherence among patients with advanced prostate cancer using oral therapies. Future Oncol. 18, 231\u2013243 (2022).","journal-title":"Future Oncol."},{"key":"948_CR131","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1080\/08870446.2022.2144923","volume":"38","author":"SJF Stewart","year":"2023","unstructured":"Stewart, S. J. F., Moon, Z. & Horne, R. Medication nonadherence: health impact, prevalence, correlates and interventions. Psychol. Health 38, 726\u2013765 (2023).","journal-title":"Psychol. Health"},{"key":"948_CR132","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00508-016-1067-9","volume":"129","author":"B Mohamad Al-Ali","year":"2017","unstructured":"Mohamad Al-Ali, B., Kramer, G., Madersbacher, S. & Berger, I. Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization. Wien. Klin. Wochenschr. 129, 380\u2013384 (2017).","journal-title":"Wien. Klin. Wochenschr."},{"key":"948_CR133","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/03007995.2021.1888704","volume":"37","author":"SJ Freedland","year":"2021","unstructured":"Freedland, S. J. et al. Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer. Curr. Med. Res. Opin. 37, 635\u2013642 (2021).","journal-title":"Curr. Med. Res. Opin."},{"key":"948_CR134","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1027\/1016-9040\/a000353","volume":"24","author":"R Hornei","year":"2019","unstructured":"Horne R., Cooper V., Wileman V., Chan A. Supporting adherence to medicines for long-term conditions. Eur. Psychol. 24, 82\u201396 (2019).","journal-title":"Eur. Psychol."},{"key":"948_CR135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080633","volume":"8","author":"R Horne","year":"2013","unstructured":"Horne, R. et al. Understanding patients\u2019 adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework. PLoS ONE 8, e80633 (2013).","journal-title":"PLoS ONE"},{"key":"948_CR136","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.pec.2015.11.004","volume":"99","author":"H Foot","year":"2016","unstructured":"Foot, H., La Caze, A., Gujral, G. & Cottrell, N. The necessity-concerns framework predicts adherence to medication in multiple illness conditions: a meta-analysis. Patient Educ. Couns. 99, 706\u2013717 (2016).","journal-title":"Patient Educ. Couns."},{"key":"948_CR137","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/pros.24097","volume":"81","author":"SS Coughlin","year":"2021","unstructured":"Coughlin, S. S., Vernon, M., Klaassen, Z., Tingen, M. S. & Cortes, J. E. Knowledge of prostate cancer among African American men: a systematic review. Prostate 81, 202\u2013213 (2021).","journal-title":"Prostate"},{"key":"948_CR138","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/pon.2043","volume":"21","author":"VH Pedersen","year":"2012","unstructured":"Pedersen, V. H., Armes, J. & Ream, E. Perceptions of prostate cancer in Black African and Black Caribbean men: a systematic review of the literature. Psychooncology 21, 457\u2013468 (2012).","journal-title":"Psychooncology"},{"key":"948_CR139","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejon.2017.04.005","volume":"29","author":"B Mulugeta","year":"2017","unstructured":"Mulugeta, B., Williamson, S., Monks, R., Hack, T. & Beaver, K. Cancer through black eyes \u2014 the views of UK based black men towards cancer: a constructivist grounded theory study. Eur. J. Oncol. Nurs. 29, 8\u201316 (2017).","journal-title":"Eur. J. Oncol. Nurs."},{"key":"948_CR140","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1258\/jms.2009.009080","volume":"16","author":"KL Austin","year":"2009","unstructured":"Austin, K. L. et al. Perceived barriers to flexible sigmoidoscopy screening for colorectal cancer among UK ethnic minority groups: a qualitative study. J. Med. Screen. 16, 174\u2013179 (2009).","journal-title":"J. Med. Screen."},{"key":"948_CR141","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.socscimed.2017.10.037","volume":"195","author":"T Brown","year":"2017","unstructured":"Brown, T. et al. Fear, family and the placing of emotion: black women\u2019s responses to a breast cancer awareness intervention. Soc. Sci. Med. 195, 90\u201396 (2017).","journal-title":"Soc. Sci. Med."},{"key":"948_CR142","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3122\/jabfm.2021.05.210149","volume":"34","author":"N Shungu","year":"2021","unstructured":"Shungu, N. & Sterba, K. R. Barriers and facilitators to informed decision-making about prostate cancer screening among black men. J. Am. Board. Fam. Med. 34, 925\u2013936 (2021).","journal-title":"J. Am. Board. Fam. Med."},{"key":"948_CR143","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1007\/s00520-021-06716-6","volume":"30","author":"OO Bamidele","year":"2022","unstructured":"Bamidele, O. O. et al. Barriers and facilitators to accessing and utilising post-treatment psychosocial support by Black men treated for prostate cancer \u2014 a systematic review and qualitative synthesis. Support. Care Cancer 30, 3665\u20133690 (2022).","journal-title":"Support. Care Cancer"},{"key":"948_CR144","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s13187-015-0832-1","volume":"31","author":"L Haynes-Maslow","year":"2016","unstructured":"Haynes-Maslow, L., Allicock, M. & Johnson, L. S. Cancer support needs for African American breast cancer survivors and caregivers. J. Cancer Educ. 31, 166\u2013171 (2016).","journal-title":"J. Cancer Educ."},{"key":"948_CR145","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11764-020-00909-4","volume":"15","author":"FO Okoro","year":"2021","unstructured":"Okoro, F. O., Song, L., Auten, B., Whitaker-Brown, C. & Cornelius, J. African-American survivors of prostate cancer: a meta-synthesis of qualitative studies. J. Cancer Surviv. 15, 40\u201353 (2021).","journal-title":"J. Cancer Surviv."},{"key":"948_CR146","doi-asserted-by":"publisher","DOI":"10.1007\/s10943-023-01845-0","author":"NM Neves","year":"2023","unstructured":"Neves, N. M., Queiroz, L. A., Cuck, G., Dzik, C. & Pereira, F. M. T. Prostate cancer and spirituality: a systematic review. J. Relig. Health https:\/\/doi.org\/10.1007\/s10943-023-01845-0 (2023).","journal-title":"J. Relig. Health"},{"key":"948_CR147","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejon.2017.06.005","volume":"30","author":"M King-Okoye","year":"2017","unstructured":"King-Okoye, M., Arber, A. & Faithfull, S. Routes to diagnosis for men with prostate cancer: men\u2019s cultural beliefs about how changes to their bodies and symptoms influence help-seeking actions. A narrative review of the literature. Eur. J. Oncol. Nurs. 30, 48\u201358 (2017).","journal-title":"Eur. J. Oncol. Nurs."},{"key":"948_CR148","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1002\/cncr.29349","volume":"121","author":"JM Salsman","year":"2015","unstructured":"Salsman, J. M., Fitchett, G., Merluzzi, T. V., Sherman, A. C. & Park, C. L. Religion, spirituality, and health outcomes in cancer: a case for a meta-analytic investigation. Cancer 121, 3754\u20133759 (2015).","journal-title":"Cancer"},{"key":"948_CR149","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13183","volume":"29","author":"R Wagland","year":"2020","unstructured":"Wagland, R. et al. Adjustment strategies amongst black African and black Caribbean men following treatment for prostate cancer: findings from the Life After Prostate Cancer Diagnosis (LAPCD) study. Eur. J. Cancer Care 29, e13183 (2020).","journal-title":"Eur. J. Cancer Care"},{"key":"948_CR150","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1534735406288084","volume":"5","author":"M White","year":"2006","unstructured":"White, M. & Verhoef, M. Cancer as part of the journey: the role of spirituality in the decision to decline conventional prostate cancer treatment and to use complementary and alternative medicine. Integr. Cancer Ther. 5, 117\u2013122 (2006).","journal-title":"Integr. Cancer Ther."},{"key":"948_CR151","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.anai.2012.11.006","volume":"110","author":"BK Ahmedani","year":"2013","unstructured":"Ahmedani, B. K., Peterson, E. L., Wells, K. E., Rand, C. S. & Williams, L. K. Asthma medication adherence: the role of God and other health locus of control factors. Ann. Allergy Asthma Immunol. 110, 75\u201379.e2 (2013).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"948_CR152","doi-asserted-by":"publisher","first-page":"564","DOI":"10.12968\/ijpn.2005.11.11.20096","volume":"11","author":"VN Thomas","year":"2005","unstructured":"Thomas, V. N., Saleem, T. & Abraham, R. Barriers to effective uptake of cancer screening among Black and minority ethnic groups. Int. J. Palliat. Nurs. 11, 564\u2013571 (2005).","journal-title":"Int. J. Palliat. Nurs."},{"key":"948_CR153","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/bjc.2016.15","volume":"114","author":"C Vrinten","year":"2016","unstructured":"Vrinten, C., Wardle, J. & Marlow, L. A. Cancer fear and fatalism among ethnic minority women in the United Kingdom. Br. J. Cancer 114, 597\u2013604 (2016).","journal-title":"Br. J. Cancer"},{"key":"948_CR154","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.socscimed.2008.05.004","volume":"67","author":"J Koffman","year":"2008","unstructured":"Koffman, J., Morgan, M., Edmonds, P., Speck, P. & Higginson, I. J. \u201cI know he controls cancer\u201d: the meanings of religion among Black Caribbean and White British patients with advanced cancer. Soc. Sci. Med. 67, 780\u2013789 (2008).","journal-title":"Soc. Sci. Med."},{"key":"948_CR155","doi-asserted-by":"publisher","first-page":"106430","DOI":"10.1016\/j.ypmed.2021.106430","volume":"145","author":"N Clarke","year":"2021","unstructured":"Clarke, N. et al. Negative emotions and cancer fatalism are independently associated with uptake of Faecal Immunochemical Test-based colorectal cancer screening: results from a population-based study. Prev. Med. 145, 106430 (2021).","journal-title":"Prev. Med."},{"key":"948_CR156","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1080\/10410236.2021.1901422","volume":"37","author":"L Lu","year":"2022","unstructured":"Lu, L., Liu, J. & Yuan, Y. C. Cultural differences in cancer information acquisition: cancer risk perceptions, fatalistic beliefs, and worry as predictors of cancer information seeking and avoidance in the U.S. and China. Health Commun. 37, 1442\u20131451 (2022).","journal-title":"Health Commun."},{"key":"948_CR157","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/1055-9965.EPI-11-0437","volume":"20","author":"RJ Beeken","year":"2011","unstructured":"Beeken, R. J., Simon, A. E., von Wagner, C., Whitaker, K. L. & Wardle, J. Cancer fatalism: deterring early presentation and increasing social inequalities? Cancer Epidemiol. Biomark. Prev. 20, 2127\u20132131 (2011).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"948_CR158","doi-asserted-by":"publisher","first-page":"102271","DOI":"10.1016\/j.eujim.2023.102271","volume":"61","author":"Z \u00d6zer","year":"2023","unstructured":"\u00d6zer, Z., Turan, G. B. & Karaman, S. Effects of fatalism perception and attitudes towards complementary and alternative medicine on medication adherence in patients with epilepsy. Eur. J. Integr. Med. 61, 102271 (2023).","journal-title":"Eur. J. Integr. Med."},{"key":"948_CR159","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.genhosppsych.2012.07.005","volume":"34","author":"RJ Walker","year":"2012","unstructured":"Walker, R. J. et al. Effect of diabetes fatalism on medication adherence and self-care behaviors in adults with diabetes. Gen. Hosp. Psychiatry 34, 598\u2013603 (2012).","journal-title":"Gen. Hosp. Psychiatry"},{"key":"948_CR160","doi-asserted-by":"crossref","unstructured":"Bamidele O., et al. Life after prostate cancer: a systematic literature review and thematic synthesis of the post-treatment experiences of Black African and Black Caribbean men. Eur. J. Cancer Care 27, e12784 (2018).","DOI":"10.1111\/ecc.12784"},{"key":"948_CR161","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/JU.0000000000001385","volume":"205","author":"ME DeWitt-Foy","year":"2021","unstructured":"DeWitt-Foy, M. E., Gam, K., Modlin, C., Kim, S. P. & Abouassaly, R. Race, decisional regret and prostate cancer beliefs: identifying targets to reduce racial disparities in prostate cancer. J. Urol. 205, 426\u2013433 (2021).","journal-title":"J. Urol."},{"key":"948_CR162","doi-asserted-by":"publisher","first-page":"1442636","DOI":"10.1080\/2331205X.2018.1442636","volume":"5","author":"M Machirori","year":"2018","unstructured":"Machirori, M., Patch, C. & Metcalfe, A. Study of the relationship between Black men, culture and prostate cancer beliefs. Cogent Med. 5, 1442636 (2018).","journal-title":"Cogent Med."},{"key":"948_CR163","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/pon.4222","volume":"25","author":"C Rivas","year":"2016","unstructured":"Rivas, C. et al. Ethnicity and the prostate cancer experience: a qualitative metasynthesis. Psychooncology 25, 1147\u20131156 (2016).","journal-title":"Psychooncology"},{"key":"948_CR164","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/sj.pcan.4500961","volume":"10","author":"K Rajbabu","year":"2007","unstructured":"Rajbabu, K. et al. Racial origin is associated with poor awareness of prostate cancer in UK men, but can be increased by simple information. Prostate Cancer Prostatic Dis. 10, 256\u2013260 (2007).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"948_CR165","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.socscimed.2007.01.007","volume":"64","author":"JD Allen","year":"2007","unstructured":"Allen, J. D., Kennedy, M., Wilson-Glover, A. & Gilligan, T. D. African-American men\u2019s perceptions about prostate cancer: implications for designing educational interventions. Soc. Sci. Med. 64, 2189\u20132200 (2007).","journal-title":"Soc. Sci. Med."},{"key":"948_CR166","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.12968\/bjon.2013.22.22.1296","volume":"22","author":"B Anderson","year":"2013","unstructured":"Anderson, B. & Marshall-Lucette, S. African and Afro-Caribbean men\u2019s experiences of prostate cancer. Br. J. Nurs. 22, 1296\u20131298, 1300\u20131302, 1304\u20131307 (2013).","journal-title":"Br. J. Nurs."},{"key":"948_CR167","doi-asserted-by":"publisher","first-page":"102080","DOI":"10.1016\/j.ejon.2021.102080","volume":"56","author":"SL Fry","year":"2022","unstructured":"Fry, S. L., Hopkinson, J. & Kelly, D. \u201cWe\u2019re talking about black men here, there\u2019s a difference\u201d; cultural differences in socialised knowledge of prostate cancer risk: a qualitative research study. Eur. J. Oncol. Nurs. 56, 102080 (2022).","journal-title":"Eur. J. Oncol. Nurs."},{"key":"948_CR168","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1365-2354.2009.01155.x","volume":"20","author":"V Nanton","year":"2011","unstructured":"Nanton, V. & Dale, J. It don\u2019t make sense to worry too much\u201d: the experience of prostate cancer in African-Caribbean men in the UK. Eur. J. Cancer Care 20, 62\u201371 (2011).","journal-title":"Eur. J. Cancer Care"},{"key":"948_CR169","unstructured":"Black British Voices. Black British Voices Project Report August 2023. The Black British Voices Research Project Team https:\/\/www.bbvp.org\/_files\/ugd\/487862_ec6ef8c150d248e193aa1617d9f47875.pdf (2023)."},{"key":"948_CR170","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1002\/cncr.34433","volume":"128","author":"JW Lillard","year":"2022","unstructured":"Lillard, J. W., Moses, K. A., Mahal, B. A. & George, D. J. Racial disparities in Black men with prostate cancer: a literature review. Cancer 128, 3787\u20133795 (2022).","journal-title":"Cancer"},{"key":"948_CR171","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.juro.2018.09.029","volume":"201","author":"AS Balakrishnan","year":"2019","unstructured":"Balakrishnan, A. S. et al. Minority recruitment trends in phase III prostate cancer clinical trials (2003 to 2014): progress and critical areas for improvement. J. Urol. 201, 259\u2013267 (2019).","journal-title":"J. Urol."},{"key":"948_CR172","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1200\/JCO.2004.03.160","volume":"22","author":"LL Adams-Campbell","year":"2004","unstructured":"Adams-Campbell, L. L. et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. J. Clin. Oncol. 22, 730\u2013734 (2004).","journal-title":"J. Clin. Oncol."},{"key":"948_CR173","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.clgc.2015.12.003","volume":"14","author":"C Ahaghotu","year":"2016","unstructured":"Ahaghotu, C., Tyler, R. & Sartor, O. African American participation in oncology clinical trials \u2014 focus on prostate cancer: implications, barriers, and potential solutions. Clin. Genitourin. Cancer 14, 105\u2013116 (2016).","journal-title":"Clin. Genitourin. Cancer"},{"key":"948_CR174","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.urology.2021.09.004","volume":"163","author":"AR Esdaille","year":"2022","unstructured":"Esdaille, A. R., Ibilibor, C., Holmes, A., Palmer, N. R. & Murphy, A. B. Access and representation: a narrative review of the disparities in access to clinical trials and precision oncology in black men with prostate cancer. Urology 163, 90\u201398 (2022).","journal-title":"Urology"},{"key":"948_CR175","unstructured":"NHS workforce. GOV.UK https:\/\/www.ethnicity-facts-figures.service.gov.uk\/workforce-and-business\/workforce-diversity\/nhs-workforce\/latest\/ (2023)."},{"key":"948_CR176","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMsr2114909","volume":"386","author":"SC Kamran","year":"2022","unstructured":"Kamran, S. C., Winkfield, K. M., Reede, J. Y. & Vapiwala, N. Intersectional analysis of U.S. medical faculty diversity over four decades. N. Engl. J. Med. 386, 1363\u20131371 (2022).","journal-title":"N. Engl. J. Med."},{"key":"948_CR177","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s13187-011-0300-5","volume":"27","author":"KR Evans","year":"2012","unstructured":"Evans, K. R., Lewis, M. J. & Hudson, S. V. The role of health literacy on African American and Hispanic\/Latino perspectives on cancer clinical trials. J. Cancer Educ. 27, 299\u2013305 (2012).","journal-title":"J. Cancer Educ."},{"key":"948_CR178","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaoncol.2019.4720","volume":"6","author":"SS Butler","year":"2020","unstructured":"Butler, S. S. et al. Racial disparities in patient-reported measures of physician cultural competency among cancer survivors in the United States. JAMA Oncol. 6, 152\u2013154 (2020).","journal-title":"JAMA Oncol."},{"key":"948_CR179","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.24395","volume":"6","author":"S Loeb","year":"2023","unstructured":"Loeb, S. et al. The effect of racial concordance on patient trust in online videos about prostate cancer: a randomized clinical trial. JAMA Netw. Open. 6, e2324395 (2023).","journal-title":"JAMA Netw. Open."},{"key":"948_CR180","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3946\/kjme.2017.53","volume":"29","author":"JA Cleland","year":"2017","unstructured":"Cleland, J. A. The qualitative orientation in medical education research. Korean J. Med. Educ. 29, 61\u201371 (2017).","journal-title":"Korean J. Med. Educ."},{"key":"948_CR181","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/jnci\/djad123","volume":"115","author":"EC Dee","year":"2023","unstructured":"Dee, E. C. et al. Leveraging national and global political determinants of health to promote equity in cancer care. J. Natl Cancer Inst. 115, 1157\u20131163 (2023).","journal-title":"J. Natl Cancer Inst."},{"key":"948_CR182","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1002\/cncr.33589","volume":"127","author":"DJ George","year":"2021","unstructured":"George, D. J. et al. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer. Cancer 127, 2954\u20132965 (2021).","journal-title":"Cancer"},{"key":"948_CR183","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/cncr.20029","volume":"100","author":"VD Woods","year":"2004","unstructured":"Woods, V. D., Montgomery, S. B. & Herring, R. P. Recruiting Black\/African American men for research on prostate cancer prevention. Cancer 100, 1017\u20131025 (2004).","journal-title":"Cancer"},{"key":"948_CR184","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1200\/EDBK_100010","volume":"37","author":"KM Winkfield","year":"2017","unstructured":"Winkfield, K. M., Flowers, C. R. & Mitchell, E. P. Making the case for improving oncology workforce diversity. Am. Soc. Clin. Oncol. Educ. Book. 37, 18\u201322 (2017).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"948_CR185","doi-asserted-by":"publisher","first-page":"pkab093","DOI":"10.1093\/jncics\/pkab093","volume":"6","author":"WJ Wang","year":"2021","unstructured":"Wang, W. J., Ramsey, S. D., Bennette, C. S. & Bansal, A. Racial disparities in access to prostate cancer clinical trials: a county-level analysis. JNCI Cancer Spectr. 6, pkab093 (2021).","journal-title":"JNCI Cancer Spectr."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00948-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00948-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00948-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T01:10:20Z","timestamp":1743815420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00948-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":185,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1038\/s41585-024-00948-x","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"10 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.N. has received personal fees from Pfizer, GSK and TESARO, Boehringer Ingelheim, travel grants from Conquer Cancer Foundation and research funding from Cancer Research UK. V.M. is employed by Northwest Permanente. B.A.M. receives funding from the Prostate Cancer Foundation (PCF), the American Society for Radiation Oncology (ASTRO), the Department of Defense, and the Sylvester Comprehensive Cancer Center. E.P. reports receiving consulting fees from Janssen and Merck Sharp & Dohme, financial support from Bayer, and non-financial support from Amgen and Astellas. D.E.S. reports personal fees from Janssen, Blue Earth, AstraZeneca and Boston Scientific outside the submitted work. P.L.N. reported receiving grants and personal fees from Bayer, Janssen and Astellas and personal fees from Boston Scientific, Dendreon, Ferring, COTA, Blue Earth Diagnostics, Myovant Sciences and Augmenix outside the submitted work. R.H. reports grants\/research support from AstraZeneca, National Institute for Health Research (NIHR) and Asthma UK (AUKCAR); honoraria\/consultation fees from AbbVie, Amgen, Astellas, AstraZeneca, Biogen, Erasmus, Idec, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp Dohme, Novartis, Pfizer, Roche, Shire Pharmaceuticals and TEVA; and is a founder and shareholder of a UCL Business company (Spoonful of Sugar) providing consultancy on supporting patients with medicine- and treatment-related behaviours to healthcare policymakers, providers and industry. Z.M. reports paid work for UCL Business Company Spoonful of Sugar. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}